Table 1.
Demographic and clinical characteristics, CTC status, CTC count, PFS and OS according to tumor subtype conversion.
| Statistics | Stable Subtype | Subtype Converters | p |
|---|---|---|---|
| Total, n (%) | 200 (100%) | 61 (100%) | |
| CTC positive, n (%) | 70 (35%) | 20 (32.8%) | 0.75 |
| CTC count, median (range) | 1 (0–200,000) | 0 (0–840) | 0.54 |
| Age at initial diagnosis, median (range) | 50 (23–87) | 48 (28–69) | 0.15 |
| Age at enrollment, median (range) | 56 (24–87) | 56 (30–78) | 0.31 |
| ER positive PT, n (%) | 151 (75.5%) | 41 (67.2%) | 0.2 |
| HER2 positive PT, n (%) | 27 (13.5%) | 24 (39.3%) | <0.001 |
| ER positive MT, n (%) | 151 (75.5%) | 31 (50.8%) | <0.001 |
| HER2 positive MT, n (%) | 27 (13.5%) | 25 (41%) | <0.001 |
| Number of metastatic sites | 0.87 | ||
| One site, n (%) | 48 (24%) | 14 (23%) | |
| Multiple sites, n (%) | 152 (76%) | 47 (77%) | |
| Site of metastasis | |||
| Bone, n (%) | 118 (59%) | 35 (57.4%) | 0.82 |
| Visceral, n (%) | 163 (81.5%) | 50 (82%) | 0.93 |
| Metastatic therapy | |||
| First line, n (%) | 25 (12.5%) | 10 (16.4%) | 0.41 |
| Second line, n (%) | 66 (33%) | 15 (24.6%) | |
| Other, n (%) | 109 (54.5%) | 36 (59%) | |
| Metastatic chemotherapy | |||
| First line, n (%) | 62 (31%) | 16 (26.2%) | |
| Second line, n (%) | 64 (32%) | 14 (23%) | 0.15 |
| Other, n (%) | 74 (38%) | 31 (50.8%) | |
| PFS, median (range) | 5 (0–76) | 5 (0–32) | 0.88 |
| OS, median (range) | 18 (0–94) | 13 (0–55) | 0.33 |